12:00 AM
 | 
Feb 10, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ADX71149: Phase IIa data

Addex said top-line data from a double-blind, international Phase IIa trial evaluating twice-daily oral ADX71149 for 8 weeks as an adjunct to a selective serotonin reuptake inhibitor (SSRI) or a serotonin/norepinephrine reuptake inhibitor (SNRI) in 121 MDD patients with anxiety symptoms do not support further development of ADX71149 in anxious depression. Specifically, ADX71149 missed the primary endpoint of improving HAM-A6 score...

Read the full 283 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >